

SEQUENCE LISTING

<110> PROUDFOOT, AMANDA
KOSCO-VILBOIS, MARIE

<120> NOVEL ANTAGONISTS OF CXCR3-BINDING CXC CHEMOKINES

<130> ARS-106

<140> US 10/517,726

<141> 2004-12-10

<150> EP 02100697.8

<151> 2002-06-12

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 73

<212> PRT

<213> Homo sapiens

<400> 1

Phe	Pro	Met	Phe	Lys	Arg	Gly	Arg	Cys	Leu	Cys	Ile	Gly	Pro	Gly	Val
1			5						10					15	

Lys	Ala	Val	Lys	Val	Ala	Asp	Ile	Glu	Lys	Ala	Ser	Ile	Met	Tyr	Pro
		20					25						30		

Ser	Asn	Asn	Cys	Asp	Lys	Ile	Glu	Val	Ile	Ile	Thr	Leu	Lys	Glu	Asn
	35						40					45			

Lys	Gly	Gln	Arg	Cys	Leu	Asn	Pro	Lys	Ser	Lys	Gln	Ala	Arg	Leu	Ile
	50					55					60				

Ile	Lys	Lys	Val	Glu	Arg	Lys	Asn	Phe
65						70		

<210> 2

<211> 73

<212> PRT

<213> Artificial sequence

<220>

<223> Antagonists of human CXCL11 having alanine substitutions

<400> 2

Phe	Pro	Met	Phe	Ala	Ala	Gly	Ala	Cys	Leu	Cys	Ile	Gly	Pro	Gly	Val
1			5						10					15	

Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
 20 25 30
 Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Lys Glu Asn
 35 40 45
 Lys Gly Gln Arg Cys Leu Asn Pro Lys Ser Lys Gln Ala Arg Leu Ile
 50 55 60
 Ile Lys Lys Val Glu Arg Lys Asn Phe
 65 70

<210> 3
 <211> 73
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Antagonists of human CXCL11 having alanine substitutions
 <400> 3

Phe Pro Met Phe Lys Arg Gly Arg Cys Leu Cys Ile Gly Pro Gly Val
 1 5 10 15
 Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
 20 25 30
 Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Ala Glu Asn
 35 40 45
 Ala Gly Gln Ala Cys Leu Asn Pro Lys Ser Lys Gln Ala Arg Leu Ile
 50 55 60
 Ile Lys Lys Val Glu Arg Lys Asn Phe
 65 70

<210> 4
 <211> 73
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> Antagonists of human CXCL11 having alanine substitutions
 <400> 4

Phe Pro Met Phe Lys Arg Gly Arg Cys Leu Cys Ile Gly Pro Gly Val
 1 5 10 15
 Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
 20 25 30

Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Lys Glu Asn
 35 40 45

Lys Gly Gln Arg Cys Leu Asn Pro Ala Ser Ala Gln Ala Ala Leu Ile
 50 55 60

Ile Lys Lys Val Glu Arg Lys Asn Phe
 65 70

<210> 5

<211> 73

<212> PRT

<213> Artificial sequence

<220>

<223> Antagonists of human CXCL11 having alanine substitutions

<400> 5

Phe Pro Met Phe Lys Arg Gly Arg Cys Leu Cys Ile Gly Pro Gly Val
 1 5 10 15

Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala Ser Ile Met Tyr Pro
 20 25 30

Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile Thr Leu Lys Glu Asn
 35 40 45

Lys Gly Gln Arg Cys Leu Asn Pro Lys Ser Lys Gln Ala Arg Leu Ile
 50 55 60

Ile Ala Ala Val Glu Ala Ala Asn Phe
 65 70

<210> 6

<211> 77

<212> PRT

<213> Homo sapiens

<400> 6

Val Pro Leu Ser Arg Thr Val Arg Cys Thr Cys Ile Ser Ile Ser Asn
 1 5 10 15

Gln Pro Val Asn Pro Arg Ser Leu Glu Lys Leu Glu Ile Ile Pro Ala
 20 25 30

Ser Gln Phe Cys Pro Arg Val Glu Ile Ile Ala Thr Met Lys Lys Lys
 35 40 45

Gly Glu Lys Arg Cys Leu Asn Pro Glu Ser Lys Ala Ile Lys Asn Leu
 50 55 60

Leu Lys Ala Val Ser Lys Glu Met Ser Lys Arg Ser Pro
 65 70 75

<210> 7
 <211> 103
 <212> PRT
 <213> Homo sapiens
 <400> 7

Thr Pro Val Val Arg Lys Gly Arg Cys Ser Cys Ile Ser Thr Asn Gln
 1 5 10 15
 Gly Thr Ile His Leu Gln Ser Leu Lys Asp Leu Lys Gln Phe Ala Pro
 20 25 30
 Ser Pro Ser Cys Glu Lys Ile Glu Ile Ile Ala Thr Leu Lys Asn Gly
 35 40 45
 Val Gln Thr Cys Leu Asn Pro Asp Ser Ala Asp Val Lys Glu Leu Ile
 50 55 60
 Lys Lys Trp Glu Lys Gln Val Ser Gln Lys Lys Lys Gln Lys Asn Gly
 65 70 75 80
 Lys Lys His Gln Lys Lys Lys Val Leu Lys Val Arg Lys Ser Gln Arg
 85 90 95
 Ser Arg Gln Lys Lys Thr Thr
 100

<210> 8
 <211> 79
 <212> PRT
 <213> Mus Musculus
 <400> 8

Phe Leu Met Phe Lys Gln Gly Arg Cys Leu Cys Ile Gly Pro Gly Met
 1 5 10 15
 Lys Ala Val Lys Met Ala Glu Ile Glu Lys Ala Ser Val Ile Tyr Pro
 20 25 30
 Ser Asn Gly Cys Asp Lys Val Glu Val Ile Val Thr Met Lys Ala His
 35 40 45
 Lys Arg Gln Arg Cys Leu Asp Pro Arg Ser Lys Gln Ala Arg Leu Ile
 50 55 60
 Met Gln Ala Ile Glu Lys Lys Asn Phe Leu Arg Arg Gln Asn Met
 65 70 75